Down 17%: Is Isis Pharmaceuticals Worth Buying Now?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 15, 4:31PM CDT
In just a few months Isis Pharmaceuticals has gone from investment darling to investment dog, dropping nearly 20% since the beginning of this year. But little has changed at Isis, suggesting the recent move lower is tied more to profit-taking...
Watch for Alnylam Pharmaceuticals to Potentially Rebound After Falling 2.78% Yesterday
Comtex SmarTrend(R) - Mon Apr 14, 5:18PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $52.02 to a high of $57.56. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $54.92 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Alnylam Pharmaceuticals (ALNY) Stock is Down Today
at The Street - Mon Apr 14, 2:15PM CDT
Alnylam Pharmaceuticals (ALNY) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in...
Alnylam Pharmaceuticals Down 21.6% Since SmarTrend Downtrend Call (ALNY)
Comtex SmarTrend(R) - Fri Apr 11, 10:06AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on March 7th, 2014 at $73.88. In approximately 1 month, Alnylam Pharmaceuticals has returned 21.58% as of today's recent price of $57.94.
Alnylam Pharmaceuticals (ALNY) Showing Signs Of A Dead Cat Bounce Today
at The Street - Fri Apr 11, 9:08AM CDT
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
PR Newswire - Thu Apr 10, 11:28AM CDT
Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Notable Two Hundred Day Moving Average Cross - ALNY
MarketNewsVideo.com - Thu Apr 10, 10:58AM CDT
In trading on Thursday, shares of Alnylam Pharmaceuticals Inc crossed below their 200 day moving average of $61.49, changing hands as low as $59.71 per share. Alnylam Pharmaceuticals Inc shares are currently trading down about 7.5% on the day.
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 5.49% Rise
Comtex SmarTrend(R) - Wed Apr 09, 4:42PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $62.78 to a high of $66.50. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $65.13 on volume of 986,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 6:00PM CDT
The EPO has upheld Alnylam's McSwiggen patent in oral opposition proceedings in Germany.
Alnylam's McSwiggen Patent Upheld in European Opposition Proceedings
Business Wire - Mon Apr 07, 7:02AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld the McSwiggen EP 1423406 ('406) patent in oral opposition proceedings in Munich, Germany. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics that the company believes are critical for achieving "drug-like" properties in siRNA, the molecules that mediate RNAi. The patent is owned by Alnylam, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck. The McSwiggen patent family comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics as a new class of medicines.
15.5% Return Seen to Date on SmarTrend Alnylam Pharmaceuticals Call (ALNY)
Comtex SmarTrend(R) - Fri Apr 04, 9:27AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on March 7th, 2014 at $73.88. In approximately 4 weeks, Alnylam Pharmaceuticals has returned 15.48% as of today's recent price of $62.45.
Alnylam to Webcast Presentation at 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 12:50 p.m. ET at the Westin Grand Central Hotel in New York City.
Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 02, 8:22AM CDT
Let's take a look a four stocks -- MannKind , GlaxoSmithKline , Myriad Genetics , and Alnylam Pharmaceuticals -- all of which could loom large in health care headlines this Wednesday morning. FDA advisory panel recommends the approval of...
Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)
Business Wire - Wed Apr 02, 7:02AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR).
Why American Capital Ltd., Alnylam Pharmaceuticals Inc., and Micron Technology Inc. are Today's 3 Be
Dan Carroll, The Motley Fool - Motley Fool - Mon Mar 31, 4:15PM CDT
Reassuring comments from Federal Reserve Chairwoman Janet Yellen helped the S&P 500 race to a 0.8% gain on the last day of March. The index closed at just over 1,872, capping off a so-so month for the markets. Still, it's been a great run for...
Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)
at The Street - Mon Mar 31, 8:55AM CDT
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate
Watch for Alnylam Pharmaceuticals to Potentially Rebound After Falling 5.20% Yesterday
Comtex SmarTrend(R) - Fri Mar 28, 4:56PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $60.28 to a high of $66.45. Yesterday, the shares fell 5.2%, which took the trading range below the 3-day low of $61.11 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
This Rapidly Evolving New Cholesterol Treatment Pathway Demands Your Attention
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 11:08AM CDT
According to the National Institutes of Health, there are 163,000 clinical studies currently under way throughout 185 countries. This is why it can sometimes be difficult to get the attention of investors when a revolutionary new treatment pathway...